UPDATE: Mizuho Securities USA Reiterates Buy Rating, Raises PT on Auxilium Pharmaceuticals on Cost Savings/Taxes

Loading...
Loading...
In a report published Wednesday, Mizuho Securities USA analyst Mario Corso reiterated a Buy rating on
Auxilium PharmaceuticalsAUXL
, and raised the price target from $33.00 to $37.00. In the report, Mizuho Securities USA noted, “Last night's ENDP bid of $28.10/AUXL share is below 2014 high and our standalone valuation, implying term revisions likely. Inclusion of restructuring cost savings/QLT tax benefits raised numbers dramatically in 2015+, with our 2014 slightly lower on revenue conservatism, DCF target to $37 from $33. We do not expect major negatives from Wednesday's testosterone FDA panel, but CV studies could be requested and/or approved indication narrowed, but little effect with Testim now <10% of 2015 revenue vs. 50% in 2013, reflecting focus on growth drivers Xiaflex, Stendra,” Auxilium Pharmaceuticals closed on Tuesday at $21.52.
Posted In: Analyst ColorPrice TargetAnalyst RatingsMario CorsoMizuho Securities USA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...